FPSAD & PI-RADS for Clinically Significant Breast Cancer Diagnosis
- Okay, here's a breakdown of the citations provided, formatted for easier readability.I've included the key information for each:
- https://doi.org/10.1038/S41598-020-76786-9 * Focus: Prostate specific antigen density and predicting clinically significant prostate cancer.
- https://doi.org/10.1016/j.urology.2022.09.007 * Focus: Comparing MRI vs.
Okay, here’s a breakdown of the citations provided, formatted for easier readability.I’ve included the key information for each:
1. yusim I, et al. (2020). Sci Rep, 10(1), 20015. https://doi.org/10.1038/S41598-020-76786-9
* Focus: Prostate specific antigen density and predicting clinically significant prostate cancer.
2. Choe S, et al. (2023). Urology, 171, 172-178. PMID: 36152871. https://doi.org/10.1016/j.urology.2022.09.007
* Focus: Comparing MRI vs. transrectal ultrasound for prostate volume/PSAD estimation and impact on cancer detection.
3. Xu B, et al.(2021). Front Oncol, 11, 1-18. https://doi.org/10.3389/FONC.2021.730638
* Focus: metabolomics profiling to differentiate prostate cancer from benign prostatic hyperplasia in the PSA gray zone.
4. Ko YH, Bh K. (2022). World J Mens Health, 40(4), 543-550.
* Focus: Questioning the applicability of Western prostate cancer screening guidelines to Asian men.
5.Scialpi M, et al. (2023). Clin Imaging, 94, 108-115. https://doi.org/10.1016/J.Clinimag.2022.11.013
* Focus: comparing simplified vs. multiparametric MRI (PI-RADS) for index lesion detection in multifocal prostate cancer.
6. Wen J, et al. (2022). front Oncol, 12, 861928. https://doi.org/10.3389/FONC.2022.861928
* Focus: Combining PI-RADS v2.1 with prostate-specific antigen density for detection of prostate cancer in the peripheral zone.
7. Zhang Y, et al.(2023). Eur Urol Oncol,6(2),123-131. DOI: 10.1016 / j.euo.2022.11.007
* Focus: Prostate cancer detection in the PSA gray zone using PSA density combined with PI-RADS v2.
8. Peng Z, et al. (2024). Small Methods, 8(10), e2301684. PMID: 38258603. https://doi.org/10.1002/smtd.202301684
* Focus: Identifying high Gleason score prostate cancer using prostate fluid metabolic fingerprinting.
9. Haroun AA, et al. (2011). Saudi J Kidney Dis Transpl, 22(2), 291-297.
* Focus: Utility of free prostate specific antigen and related parameters in diagnosing prostate cancer.
10. Naya Y, et al. (incomplete citation) Urology.
* focus: Volume indexes of prostate-specific antigen enhancing prediction of extraprostatic disease.
Key Themes/Observations:
* PSA Density: A recurring theme is the use of Prostate Specific Antigen Density (PSAD) as a tool to improve prostate cancer detection, particularly in the “gray zone” (where PSA levels are borderline).
* PI-RADS: The PI-RADS (Prostate Imaging reporting and Data System) scoring system for MRI is frequently used and evaluated in thes studies.
* Metabolomics: Some research explores the use of metabolomics (studying small molecule chemical fingerprints) to differentiate between cancer and benign conditions.
* MRI advancements: Studies are comparing different MRI techniques to improve detection and characterization of prostate cancer.